Alliancebernstein L.P. Buys 146,677 Shares of Halozyme Therapeutics, Inc. $HALO

Alliancebernstein L.P. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,215,109 shares of the biopharmaceutical company’s stock after buying an additional 146,677 shares during the period. Alliancebernstein L.P.’s holdings in Halozyme Therapeutics were worth $205,156,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Stifel Financial Corp lifted its holdings in Halozyme Therapeutics by 79.7% in the 4th quarter. Stifel Financial Corp now owns 30,768 shares of the biopharmaceutical company’s stock worth $1,471,000 after purchasing an additional 13,647 shares during the last quarter. Hsbc Holdings PLC raised its position in shares of Halozyme Therapeutics by 52.0% in the fourth quarter. Hsbc Holdings PLC now owns 9,615 shares of the biopharmaceutical company’s stock valued at $462,000 after purchasing an additional 3,289 shares during the period. AXA S.A. lifted its stake in shares of Halozyme Therapeutics by 22.1% in the fourth quarter. AXA S.A. now owns 131,891 shares of the biopharmaceutical company’s stock worth $6,306,000 after buying an additional 23,835 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $521,000. Finally, Baird Financial Group Inc. boosted its holdings in shares of Halozyme Therapeutics by 2.0% during the 4th quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company’s stock worth $532,000 after buying an additional 221 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total value of $294,720.00. Following the completion of the transaction, the director owned 46,952 shares of the company’s stock, valued at $3,459,423.36. This represents a 7.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $46,598,493.69. This represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 84,000 shares of company stock valued at $4,827,320 over the last ninety days. 2.90% of the stock is owned by insiders.

Analysts Set New Price Targets

HALO has been the topic of several recent analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 7th. Leerink Partnrs cut Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 13th. HC Wainwright increased their target price on Halozyme Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Finally, Benchmark downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 7th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and a consensus price target of $67.11.

Halozyme Therapeutics Stock Up 2.0%

NASDAQ HALO opened at $74.82 on Thursday. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The firm has a 50-day simple moving average of $61.93 and a 200 day simple moving average of $59.59. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $74.94. The stock has a market cap of $8.75 billion, a PE ratio of 17.12, a PEG ratio of 0.42 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. The firm had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.